Peritoneal Mesothelioma: A Rare but Treatable Form of Asbestos Cancer

Peritoneal mesothelioma is a rare cancer that forms in the peritoneum—the thin layer of tissue lining the abdominal cavity and surrounding internal organs. Although it accounts for only about 10–20% of mesothelioma cases, peritoneal mesothelioma is strongly linked to asbestos exposure and may respond more favorably to certain treatments than other types of the disease.

The cancer often begins decades after initial exposure to asbestos. Like pleural mesothelioma, it is almost always caused by inhaling or ingesting microscopic asbestos fibers, which become lodged in tissue and trigger inflammation, scarring, and eventually malignant transformation.

New Treatment Options Offer Hope to Families

Peritoneal mesothelioma is a rare and aggressive cancer, but advances in treatment are improving outcomes. In 2025, patients have more options than ever before—including CRS-HIPEC surgery, immunotherapy, and personalized multimodal treatment plans based on tumor type and stage.

We’ve created a detailed guide to help patients and families understand the full landscape of care. Read our in-depth page on Peritoneal Mesothelioma Treatments and Prognosis in 2025 →

Understanding Your Diagnosis

Peritoneal mesothelioma is a rare cancer that forms in the lining of the abdomen, called the peritoneum. While it shares a name with other types of mesothelioma, it behaves differently from forms that develop in the chest (pleural mesothelioma), around the heart (pericardial mesothelioma), or in the testicles (testicular mesothelioma). Understanding the specifics of your diagnosis—especially the cell type, or histology—is a key step in making informed decisions about treatment.

After a biopsy is taken, a pathologist examines the tumor tissue under a microscope. This allows your medical team to confirm the diagnosis and determine the histologic subtype, which refers to how the cancer cells are structured and how aggressively they are likely to behave. You’ll often see this information on a pathology report, but it may not always be explained clearly. If you’re unsure what your report means, your doctor can walk through it with you—it’s okay to ask.

There are three main cell types seen in peritoneal mesothelioma:

• Epithelioid mesothelioma
  This is the most common type. The cells are more organized and often respond better to treatment. Patients with epithelioid tumors tend to have the most favorable outcomes.

• Sarcomatoid mesothelioma
  This less common type has cells that look more disorganized or spindle-shaped. It tends to grow and spread more quickly and is typically harder to treat.

• Biphasic mesothelioma
  A mix of epithelioid and sarcomatoid cells. The prognosis varies depending on which cell type is more dominant in the tumor sample.

Histology plays a major role in determining your treatment plan. For example, patients with epithelioid tumors are more likely to be candidates for surgery and heated chemotherapy (HIPEC), while those with sarcomatoid tumors may be referred more quickly for systemic therapies or clinical trials. Understanding what kind of mesothelioma you have is the first step in understanding what’s next.

Asbestos Exposure Is the Primary Cause of Peritoneal Mesothelioma

Peritoneal mesothelioma is not caused by genetics, diet, or random chance. It is overwhelmingly linked to asbestos exposure—specifically to the ingestion or internal migration of microscopic asbestos fibers.

When asbestos-containing materials are cut, sanded, or disturbed, they release sharp, needle-like fibers into the air. These fibers can be swallowed directly or inhaled and later migrate through the lymphatic system into the peritoneum—the thin membrane that lines the abdominal cavity. Over time, these fibers cause inflammation, scarring, and genetic damage that can eventually lead to cancer.

This process is slow. Most people diagnosed with peritoneal mesothelioma were exposed to asbestos 20 to 50 years earlier, often through occupational contact or secondhand exposure. In some cases, even short-term or non-industrial exposure may be enough to trigger the disease. There is no known safe level of asbestos exposure—and peritoneal mesothelioma is one of the clearest examples of an environmental cancer with a preventable cause.

How Asbestos Fibers Reach the Abdominal Cavity

While it's easy to understand how inhaled asbestos fibers reach the lungs, the journey to the abdominal cavity is less obvious—but no less dangerous. Peritoneal mesothelioma is believed to develop when asbestos fibers enter the body through inhalation or ingestion and then migrate to the peritoneum, the lining of the abdominal cavity.

Asbestos Fibers Enter the Body

Asbestos typically enters the body through two primary routes:

• Inhalation: The most common route. Disturbing asbestos-containing materials—such as insulation, floor tiles, or brake pads—can release microscopic fibers into the air. These fibers are easily inhaled and may become lodged deep within the lungs.

• Ingestion: Asbestos fibers can also be swallowed, either directly (via contaminated food, water, or hands) or indirectly. Inhaled fibers trapped in mucus may be coughed up and then swallowed—a process known as mucociliary clearance.

• Perineal Talc Use (Women): In women, long-term perineal use of talcum powder—especially if contaminated with asbestos—may allow fibers to migrate through the reproductive tract and into the peritoneal cavity. This route of exposure is believed to contribute to some cases of peritoneal mesothelioma and ovarian cancer, particularly in individuals without known occupational or secondary asbestos exposure (Malpica et al., 2020).

Fibers Migrate to the Peritoneum

Once inside the body, asbestos fibers can travel through biological systems to reach the abdomen. This migration is thought to occur through several mechanisms:

• Lymphatic Transport: The lymphatic system helps drain fluids and waste from tissues and plays a central role in immune defense. Asbestos fibers may enter this system from the lungs or gastrointestinal tract and be transported to lymph nodes and eventually to the peritoneal cavity (Malpica et al., 2020; Brandl et al., 2020).

• Mucociliary Clearance and GI Translocation: Inhaled fibers that are trapped in the upper airways can be moved upward by cilia, coughed out, and swallowed. From there, they may pass through the digestive tract and enter the abdominal cavity (Brandl et al., 2020).

• Direct Tissue Penetration: Though less clearly understood, it is possible that some asbestos fibers physically migrate through tissues or are carried into the abdominal cavity during inflammatory or immune responses. This mechanism has been observed in other forms of mesothelioma and is being further studied in peritoneal cases (Yaşar et al., 2024).

What Happens Once the Fibers Arrive

Once asbestos fibers lodge in the peritoneal lining, they can cause:

• Chronic Inflammation: The body’s immune system attempts to neutralize the foreign fibers, resulting in persistent inflammation that damages surrounding cells.

• Physical Cellular Damage: Asbestos fibers are rigid and sharp. When embedded in tissue, they can pierce cell membranes and organelles, leading to dysfunction or death of the affected cells.

• Genetic Mutations: Over time, the combination of inflammation and physical damage may lead to mutations in critical genes that regulate cell growth and repair. This can eventually result in the development of cancerous cells (Malpica et al., 2020).

As with other forms of mesothelioma, the process from initial exposure to cancer formation is slow. Most patients diagnosed with peritoneal mesothelioma were exposed to asbestos 20 to 60 years earlier, underscoring the long latency period and the importance of monitoring individuals with known exposure.

How People Were Typically Exposed to Asbestos

Asbestos was used across thousands of products and industries throughout the 20th century, especially before regulations limited its use in the late 1970s and beyond. Its resistance to heat, fire, and corrosion made it a mainstay in construction, shipbuilding, automotive repair, and many household goods. Below are the most common ways people were exposed to asbestos that later contributed to cases of peritoneal mesothelioma.

• Occupational Exposure: For most patients diagnosed with peritoneal mesothelioma, the source of exposure was the workplace. Construction workers frequently handled asbestos-laced insulation, joint compounds, and asbestos-cement products. Shipyard workers were exposed to asbestos in pipe lagging, boiler rooms, and bulkhead insulation. Auto mechanics dealt with asbestos in brakes, clutches, and gaskets. In these environments, workers regularly inhaled or ingested asbestos fibers that contaminated the air, their hands, and even their food during breaks. Learn more about occupational asbestos exposure.

• Secondary Exposure (Take-Home Asbestos): The danger didn’t stay at the job site. Workers unknowingly carried asbestos fibers home on their clothing, boots, and hair. Family members—especially spouses and children—could then be exposed to the fibers during routine activities like doing laundry or hugging a loved one returning from work. Many peritoneal mesothelioma patients never worked with asbestos directly but were exposed secondhand through a family member. Learn more about secondary asbestos exposure.

• Industry-Specific Exposure: Some industries posed exceptionally high risks. Construction and shipbuilding led the list, but textile mills, power plants, oil refineries, and paper manufacturing also used asbestos heavily. Even white-collar employees working in buildings where asbestos was present—such as schools, hospitals, or offices—could inhale airborne fibers if insulation or ceiling panels were disturbed. In many workplaces, asbestos was not a localized hazard; it was an ambient danger affecting everyone in the area. Learn more about industries with asbestos exposure.

• Exposure from Consumer Products: Asbestos wasn’t limited to heavy industry—it was also in homes. The mineral was found in ironing board covers, oven mitts, toasters, fake fireplace logs, and attic insulation. Even some popular products like Kent Micronite cigarettes and Zippo lighters contained asbestos components. For decades, people interacted with these items daily, never knowing the health risks. This everyday contact, especially in poorly ventilated areas, likely contributed to many long-term asbestos-related diseases, including peritoneal mesothelioma. Learn more about asbestos-containing products.

Protect Yourself and Your Loved Ones with a Free Asbestos Health Test: Peritoneal mesothelioma is rare—but other asbestos-related illnesses, including asbestosis and pleural mesothelioma, are more common and often go undetected. If you or a loved one ever worked around asbestos, or lived with someone who did, you may have been exposed without realizing it. Early detection is key. Call 833-4-ASBESTOS today to schedule a free asbestos health test.

Why Exposure History Matters

Because peritoneal mesothelioma has such a long latency period—typically 20 to 60 years after asbestos exposure—many patients are unaware they were ever exposed. Others may have had secondhand contact through a family member’s work clothing or contaminated home products. For this reason, it’s crucial to tell your healthcare provider about any potential exposure to asbestos, no matter how distant or indirect.

When peritoneal mesothelioma is caught early—before widespread abdominal involvement—patients have a greater chance of benefiting from surgery and chemotherapy. In some cases, survival can be extended for many years.

How Is Peritoneal Mesothelioma Diagnosed?

Diagnosing peritoneal mesothelioma is challenging due to its rarity, vague symptoms, and similarity to more common abdominal conditions. Symptoms like abdominal pain, bloating, or ascites (fluid buildup) often go unnoticed or are misdiagnosed as gastrointestinal or gynecological issues, delaying critical care. In a UK-Ireland study, only 25.8% of patients were referred for surgical evaluation based on initial suspicion, highlighting the difficulty clinicians face (Brandl et al., 2020). Early diagnosis is vital, as it opens the door to life-extending treatments like cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). A combination of clinical suspicion, imaging, biopsy, and specialized testing—especially in those with a history of asbestos exposure—is essential for accurate diagnosis.

Why Diagnosis Is Difficult

Peritoneal mesothelioma is rare, with many doctors encountering only a few cases in their careers. Its symptoms mimic conditions like ovarian cancer, irritable bowel syndrome, or appendiceal tumors, leading to frequent misdiagnosis or delays. In one study, 15% of women were diagnosed incidentally during surgery for presumed gynecological conditions (Malpica et al., 2020). Additionally, asbestos exposure history—direct or secondary—is often undocumented, complicating suspicion of mesothelioma, particularly in non-occupational cases like talc-related exposure. Despite these challenges, a national review found that asbestos exposure was confirmed in 9% of women with peritoneal mesothelioma, with 69% reporting a family history of other cancers, suggesting environmental or syndromic risks (Malpica et al., 2020).

The Diagnostic Process

Diagnosing peritoneal mesothelioma involves a multi-step approach, starting with recognizing symptoms and exposure history, followed by imaging and tissue confirmation. Here’s how it typically unfolds:

• Symptoms and History: Persistent abdominal complaints—such as bloating, early satiety, diffuse pain, or unexplained weight loss—prompt investigation, especially if there’s a known or suspected asbestos exposure history, even decades prior.

• Imaging: Cross-sectional imaging is the first step to identify abnormalities.

  • CT Scans: Contrast-enhanced computed tomography (CT) is the primary tool, detecting peritoneal thickening, nodules, masses, or ascites. It helps assess disease extent and surgical candidacy (Brandl et al., 2020).

  • MRI or PET Scans: Magnetic resonance imaging (MRI), particularly with diffusion-weighted imaging, may evaluate small bowel involvement or tumor burden. Positron emission tomography (PET) is less common but can detect distant spread or recurrence (Yaşar et al., 2024).

• Biopsy: Tissue confirmation is required for a definitive diagnosis.

  • Core Needle Biopsy: Guided by imaging, this is used when a discrete mass or thickening is present.

  • Laparoscopic Biopsy: Allows direct visualization of the peritoneum and sampling of multiple areas, especially when imaging is inconclusive or surgical resectability is being assessed.

Confirming the Diagnosis with Histology

Histology refers to the microscopic examination of tumor cells to determine their structure and behavior. In peritoneal mesothelioma, histological analysis not only confirms that the tumor is mesothelial in origin but also identifies the specific cell type, which has important implications for treatment and prognosis. There are three recognized histologic subtypes: epithelioid, biphasic, and sarcomatoid. Epithelioid mesothelioma, characterized by more organized and uniform cells, is the most common and generally responds better to treatment. Biphasic tumors contain a mix of epithelioid and sarcomatoid features, while sarcomatoid tumors consist of spindle-shaped cells and tend to be the most aggressive and resistant to therapy.

Most cases of peritoneal mesothelioma (MPeM) are of the epithelioid subtype, which is associated with better outcomes compared to other subtypes like sarcomatoid or biphasic. Immunohistochemistry (IHC) is a critical diagnostic tool used to differentiate MPeM from other malignancies, such as metastatic adenocarcinomas originating from the gastrointestinal tract or ovaries. IHC involves staining tissue samples with antibodies that bind to specific proteins expressed by the tumor cells, helping pathologists identify the tumor's origin and subtype.

The following table summarizes key IHC markers used in diagnosis:

Pathologists use a panel of at least two positive and two negative markers for accuracy, as no single marker is fully specific. This precise analysis ensures the correct diagnosis, guiding treatment planning (Malpica et al., 2020).

Blood Tests and Emerging Tools

No blood test definitively diagnoses peritoneal mesothelioma, but some markers may support evaluation:

• CA-125, CEA, CA 19-9: These are sometimes elevated but nonspecific, aiding in monitoring rather than diagnosis. CA-125 was elevated in 60% of women tested in one study (Malpica et al., 2020).

• Routine Labs: May show anemia, elevated inflammatory markers, or hypoalbuminemia, indicating advanced disease.

Researchers are developing liquid biopsies (detecting tumor DNA in blood) and AI-based imaging tools, which may enable earlier, less invasive diagnosis in the future, though these are not yet standard practice.

Special Considerations for Women with Peritoneal Mesothelioma

While peritoneal mesothelioma is more common in men—due to historically higher rates of occupational asbestos exposure—women with the disease face distinct diagnostic, clinical, and legal challenges that deserve attention.

Misdiagnosis and Delayed Detection

Symptoms like abdominal pain, bloating, or pelvic pressure are often misattributed to more common gynecological conditions such as ovarian cysts, uterine fibroids, or endometriosis. This can delay diagnosis and appropriate referral. In one large study of women with peritoneal mesothelioma, nearly 15% were diagnosed incidentally during surgery for presumed reproductive conditions (Malpica et al., 2020). For this reason, it’s important that gynecologists and primary care physicians include mesothelioma in the differential diagnosis—particularly in patients with a history of asbestos exposure.

Prognosis and Tumor Type

Interestingly, some studies suggest that women with peritoneal mesothelioma may experience slightly better survival rates than men. This may be due in part to a higher incidence of low-grade subtypes, such as well-differentiated papillary mesothelioma (WDPM) or multicystic mesothelioma, both of which tend to grow slowly and respond well to surgery. Accurate histological diagnosis is crucial, as these low-grade tumors often require a different treatment approach and may not necessitate the same aggressive chemotherapy regimens used in high-grade disease.

Fertility and Family Planning

For younger women, especially those who may wish to have children in the future, treatment planning should include a discussion of fertility preservation. CRS-HIPEC can impact reproductive organs, either directly or through necessary removal of the uterus or ovaries. If fertility is a concern, talk to your care team about egg freezing, embryo preservation, or referral to a reproductive endocrinologist before undergoing surgery or chemotherapy.

The Risk from Cosmetic Talc Use

Unlike many men, women are more likely to have been exposed to asbestos through non-occupational routes—including the use of cosmetic talcum powder in the genital area. Talc and asbestos are both silicate minerals that often occur together geologically, and historical talc products—including some well-known brands—have been found to contain asbestos contamination.

Long-term perineal use of talcum powder may allow fibers to travel through the reproductive tract and into the abdominal cavity, where they can embed in the peritoneum. This exposure pathway has been linked not only to peritoneal mesothelioma, but also to ovarian cancer. If you regularly used talcum powder and have been diagnosed with mesothelioma, this history may be relevant for both your medical care and your legal rights.

Staging Peritoneal Mesothelioma

Unlike pleural mesothelioma, which affects the lungs and has a standardized staging system, peritoneal mesothelioma lacks a universally adopted framework like TNM (Tumor–Node–Metastasis). The disease’s rarity and diffuse spread across the abdominal lining (peritoneum) make traditional staging challenging, as it rarely forms discrete tumors or spreads to lymph nodes in predictable patterns. Instead, specialists rely on specialized tools—the Peritoneal Cancer Index (PCI) and Completeness of Cytoreduction (CC) score—to assess disease extent, guide treatment decisions, and predict outcomes. These tools, widely used in clinical practice, help determine whether aggressive treatments like cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are feasible, offering hope for better survival when the disease is caught early (Yaşar et al., 2024).

Why Traditional Staging Doesn’t Work

Peritoneal mesothelioma typically spreads across the peritoneal surfaces in a scattered, diffuse manner rather than forming localized masses. This pattern makes TNM staging, designed for cancers with defined tumor, lymph node, and metastasis characteristics, ineffective for assessing prognosis or planning therapy. As a result, clinicians have developed alternative systems like the PCI to quantify tumor burden during diagnosis and surgical planning, providing a more reliable framework for managing this complex disease (Liu et al., 2014).

Peritoneal Cancer Index (PCI)

The Peritoneal Cancer Index (PCI) is a numeric scoring system that measures the extent of peritoneal mesothelioma within the abdomen. It’s a critical preoperative tool used to evaluate tumor burden and determine whether surgery is a viable option. The PCI divides the abdomen and pelvis into 13 regions, including nine abdominal quadrants and four areas of the small bowel mesentery. Each region is scored based on the size of the largest tumor nodule:

• 0: No visible tumor.

• 1: Tumor nodules ≤0.5 cm.

• 2: Tumor nodules 0.5 cm–5 cm.

• 3: Tumor nodules >5 cm or a confluence of nodules.

Scores are summed to calculate a total PCI ranging from 0 to 39. Lower scores indicate less disease and better prospects for successful treatment. In studies, patients with lower PCI scores had significantly longer survival after CRS-HIPEC (Yaşar et al., 2024; Liu et al., 2014).

Completeness of Cytoreduction (CC) Score

For patients undergoing cytoreductive surgery, the Completeness of Cytoreduction (CC) score evaluates how much tumor remains after the procedure. The goal of cytoreduction is to remove all visible tumors, as smaller residual disease responds better to follow-up therapies like HIPEC. The CC score, assessed post-surgery, is a major prognostic indicator:

• CC-0: No visible residual disease (ideal outcome, best survival).

• CC-1: Residual nodules ≤2.5 mm (favorable, responsive to HIPEC).

• CC-2: Residual nodules 2.5 mm–2.5 cm (significant disease, poorer survival).

• CC-3: Residual nodules >2.5 cm or bulky disease (extensive disease, poor outcomes).

Patients with CC-0 or CC-1 scores, often associated with lower preoperative PCI, have markedly better survival. Incomplete cytoreduction (CC-2 or CC-3) is a strong predictor of poorer prognosis (Liu et al., 2014).

Tools for Staging and Surgical Planning

To assess disease extent and plan treatment, specialists use a combination of imaging, surgical evaluation, and histopathological analysis. These tools help estimate PCI preoperatively and guide intraoperative decisions:

• Imaging:

  • CT Scan with Contrast: The primary tool to assess tumor spread, nodularity, ascites, and involvement of bowel or omentum.

  • MRI (Diffusion-Weighted): Evaluates small bowel involvement and resectability.

  • PET/CT: Occasionally used to identify nodal or distant metastases, though its role is limited in peritoneal disease.

• Surgical Staging:

  • Diagnostic Laparoscopy: Provides direct visualization of the peritoneum to estimate PCI and assess surgical feasibility.

  • Intraoperative Findings: The most accurate method to determine disease extent and guide CC scoring during surgery.

• Histopathological Factors:

  • Tumor Subtype: Epithelioid, biphasic, or sarcomatoid subtypes influence prognosis, with epithelioid offering the best outcomes.

  • Depth of Invasion: Tumors invading fat or organs indicate more aggressive disease.

  • Lymph Node Involvement: Rare but worsens prognosis when present (Sharma et al., 2011).

Clinical Implications of PCI and CC

The PCI and CC scores are essential for tailoring treatment plans and setting realistic expectations. Their implications are summarized below:

A low PCI (<20) increases the likelihood of achieving a CC-0 or CC-1 score, which is critical for long-term survival. These scores help clinicians decide whether aggressive surgery is appropriate or if alternative treatments, like systemic chemotherapy, are more suitable (Yaşar et al., 2024).

Localized vs. Advanced Disease

Although peritoneal mesothelioma is not staged using the traditional TNM system, doctors often group the disease into two broad categories—localized and advanced—based on how far the cancer has spread within the abdomen and how aggressive it appears under the microscope. This distinction is critical because it directly influences whether a patient is a candidate for potentially curative surgery or if care will focus on symptom relief and quality of life.

Localized Disease

Localized peritoneal mesothelioma refers to cases where the tumor burden is limited—usually indicated by a low Peritoneal Cancer Index (PCI), minimal or no involvement of the small bowel, and a favorable histological subtype (typically epithelioid). In these situations:

• The cancer is largely confined to the peritoneal surfaces and may not have deeply invaded organs or tissue.

• Patients are often eligible for cytoreductive surgery with HIPEC, which offers the best chance at long-term survival or even remission.

• The disease may be detected earlier, especially in patients monitored due to asbestos exposure or persistent abdominal symptoms.

Early intervention in localized cases is key, as outcomes are significantly better when the disease can be fully or nearly fully removed during surgery (CCR-0 or CCR-1).

Advanced Disease

Advanced disease means the cancer has spread widely throughout the abdominal cavity or shows more aggressive features. This may include:

• A high PCI score (indicating extensive tumor spread across multiple abdominal regions).

• Involvement of the small bowel serosa, which makes complete surgical removal difficult or impossible.

• Infiltration into critical structures such as the liver, stomach, or pelvic organs.

• Sarcomatoid or biphasic histology, which are less responsive to treatment and carry a poorer prognosis.

In these cases, curative surgery is usually not an option. Instead, treatment focuses on systemic chemotherapy, symptom management, and palliative care to improve quality of life. This may include managing ascites, pain, or digestive symptoms through supportive interventions.

Even in advanced cases, some patients benefit from multimodal care or clinical trials—especially when guided by a multidisciplinary mesothelioma team. However, understanding whether the disease is localized or advanced is one of the most important steps in building an appropriate and realistic treatment plan.

What Are the Symptoms of Peritoneal Mesothelioma?

Peritoneal mesothelioma typically develops over decades, and its symptoms often appear slowly—making early diagnosis difficult. Unlike pleural mesothelioma, which affects the lungs, peritoneal mesothelioma impacts the lining of the abdomen, so its symptoms are usually gastrointestinal or systemic rather than respiratory. Most signs are nonspecific and can mimic common digestive or gynecological conditions, contributing to frequent misdiagnosis or delays in treatment.

In the UK-Ireland national study, nearly all patients presented with vague abdominal symptoms before diagnosis, with abdominal pain, distension, and ascites (fluid buildup) being the most common complaints (Brandl et al., 2020).

Most Common Symptoms

• Abdominal Pain or Discomfort: One of the earliest and most frequently reported symptoms. Pain may be dull, persistent, or cramping.

• Abdominal Swelling or Bloating: Caused by ascites—fluid accumulating in the peritoneal cavity. This is often mistaken for weight gain, liver disease, or ovarian issues.

• Unexplained Weight Loss: Many patients report unintended weight loss over several weeks or months, often accompanied by fatigue.

• Digestive Issues: Including loss of appetite, nausea, early satiety (feeling full quickly), constipation, or altered bowel habits.

• Fatigue: A common but nonspecific symptom, often related to cancer-related inflammation or poor nutrient absorption.

• New or Worsening Hernia: In some patients, increased intra-abdominal pressure caused by ascites can lead to the development or enlargement of a hernia, especially in the groin or umbilical region.

• Palpable Mass: Less commonly, a patient or physician may feel a firm mass in the abdomen or pelvis, especially in more advanced cases.

Rare but Possible Symptoms

• Fever or Night Sweats: May occur if the disease causes infection-like inflammation in the abdominal lining.

• Lower Back Pain or Pelvic Pressure: Resulting from tumor growth pressing against nerves or organs.

• Shortness of Breath: In rare cases, peritoneal disease may contribute to fluid buildup that affects the diaphragm or pleural space, especially in advanced stages.

Why Symptoms Are Often Missed

Because these symptoms are so common in many non-cancerous conditions—like irritable bowel syndrome (IBS), ovarian cysts, or gastrointestinal infections—peritoneal mesothelioma is rarely suspected early on. In the study by Malpica et al. (2020), 15% of women were diagnosed incidentally, often during surgeries for other conditions such as hysterectomy, hernia repair, or evaluation of suspected ovarian cancer.

In men and women alike, symptoms may progress for months or even years before the correct diagnosis is made. This delay is critical: patients diagnosed early and referred to specialized centers for surgery and HIPEC may experience significantly improved survival (Yaşar et al., 2024).

Treatment Options for Peritoneal Mesothelioma

Peritoneal mesothelioma is a rare but increasingly treatable form of asbestos-related cancer. While no formal universal guidelines exist, treatment strategies have evolved significantly in recent years—especially with the growing success of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). This approach was pioneered in the 1980s by Dr. Paul Sugarbaker, who also developed the Peritoneal Cancer Index (PCI)—a scoring system still used today to assess tumor burden and guide surgical decisions.

Recent multi-center studies confirm that aggressive, personalized treatment using CRS-HIPEC can lead to long-term survival in select patients (Yaşar et al., 2024; Brandl et al., 2020). In the Yaşar study, patients who underwent CRS-HIPEC had a 1-year survival rate of 95% and a 2-year survival rate of over 83%, with some patients living five years or more after diagnosis. These outcomes represent a significant improvement over historical survival rates and demonstrate that, with early diagnosis and access to specialized care, peritoneal mesothelioma is no longer uniformly fatal.

CRS-HIPEC: The Best Option for Many Patients

Cytoreductive surgery (CRS) is the first step in treating eligible patients with peritoneal mesothelioma. The goal is to surgically remove all visible tumors from the surfaces of the abdominal cavity—including the peritoneum, omentum, diaphragm, and, in some cases, portions of involved organs like the colon, spleen, or stomach.

Once the visible disease is removed, the second phase—hyperthermic intraperitoneal chemotherapy (HIPEC)—is performed during the same surgery. A heated chemotherapy solution is circulated throughout the abdominal cavity, typically for 60 to 90 minutes. The fluid bathes the peritoneal surfaces, delivering high concentrations of chemotherapy directly to areas most at risk for microscopic residual disease.

The heat enhances the effectiveness of the chemotherapy by increasing drug penetration and making cancer cells more vulnerable to treatment. Because the drugs are applied locally rather than systemically, HIPEC also reduces exposure to the rest of the body—minimizing side effects.

This two-part approach is more than just a treatment—it represents the most significant advancement in survival for patients with peritoneal mesothelioma. When complete or near-complete tumor removal is possible, CRS-HIPEC offers a realistic path to long-term disease control—and, in some cases, years of extended survival.Effectiveness: In the largest European cohort to date, patients treated with CRS-HIPEC had a median overall survival of 44.6 months and a 1-year survival rate of 95%—substantially higher than those treated with chemotherapy alone (Yaşar et al., 2024).

• Procedure Details: CRS may include removal of the omentum, peritoneal lining, parts of the diaphragm, and—in some cases—sections of involved bowel or other organs. HIPEC typically involves heated cisplatin, mitomycin C, or doxorubicin circulated throughout the abdominal cavity for 60–90 minutes.

• Selection Criteria: Patients are evaluated based on tumor burden (measured by the Peritoneal Cancer Index), overall health, and potential for complete or near-complete tumor removal (Brandl et al., 2020).

Additional Surgical Techniques

Diagnostic Laparoscopy
Minimally invasive staging to assess tumor spread and feasibility of CRS-HIPEC. It helps avoid unnecessary open surgery if the disease is unresectable.

Palliative Debulking Surgery
In cases where curative resection is not possible, limited surgery may be performed to reduce symptoms caused by tumor bulk or bowel obstruction. While not curative, it may improve comfort and quality of life.

Systemic Chemotherapy

Chemotherapy is the primary treatment for patients who are not candidates for surgery due to advanced disease, comorbidities, or widespread metastasis.

• Common Regimens: Most patients receive platinum-based combinations such as cisplatin or carboplatin with pemetrexed—drugs also used in pleural mesothelioma.

• Response Rates: While less effective than CRS-HIPEC, chemotherapy can offer temporary disease control. In the Yaşar et al. (2024) study, patients treated with systemic chemotherapy alone had a median survival of just 11.2 months—less than one-third the survival seen in the surgical group.

• Newer Approaches: Ongoing studies are investigating immunotherapy and targeted agents. Early results suggest that checkpoint inhibitors may be beneficial in some patients, though they are not yet standard care.

Immunotherapy for Peritoneal Mesothelioma

Immunotherapy is an emerging treatment approach for peritoneal mesothelioma that uses the body’s own immune system to recognize and attack cancer cells. While not yet a standard first-line therapy for most patients, immunotherapy is gaining momentum—especially for those who are not candidates for surgery or whose disease has progressed after chemotherapy.

Mesothelioma tumors can suppress the immune response, allowing them to grow unchecked. Immunotherapy drugs—particularly immune checkpoint inhibitors—help remove these suppressive signals, restoring the immune system’s ability to identify and destroy cancer cells. To do this, they target specific molecular "checkpoints" that act as brakes on immune activity. The two most commonly targeted pathways in mesothelioma treatment are PD-1/PD-L1 and CTLA-4—both of which play a critical role in how immune cells recognize and respond to tumors.

Common Immunotherapy Drugs Used

The most commonly used immunotherapy agents in mesothelioma target the PD-1/PD-L1 and CTLA-4 pathways. These include:

• Nivolumab (Opdivo) – a PD-1 inhibitor

• Pembrolizumab (Keytruda) – another PD-1 inhibitor

• Ipilimumab (Yervoy) – a CTLA-4 inhibitor

Some regimens use these drugs in combination—for example, nivolumab + ipilimumab has shown improved survival in pleural mesothelioma and is now being explored for peritoneal mesothelioma in ongoing trials.

What the Research Shows

Although research on immunotherapy specifically for peritoneal mesothelioma is still limited, early studies suggest that it may help certain patients—especially those with non-epithelioid tumors or cancers that express high levels of PD-L1, a protein that helps tumors hide from the immune system.

Two major clinical trials provide encouraging clues:

• Keynote 28 tested the immunotherapy drug pembrolizumab (Keytruda) in patients with mesothelioma whose tumors had at least some PD-L1 expression (≥1%). About 72% of patients saw their cancer stabilize or shrink, and 20% had a measurable reduction in tumor size.

• CheckMate 743 looked at a combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in pleural mesothelioma (which affects the lining around the lungs). Patients treated with this combination lived a median of 15.9 months, compared to 14.1 months with standard chemotherapy. While this trial focused on pleural disease, the same immune pathways are involved in peritoneal mesothelioma—suggesting the combination may also help patients with abdominal disease.

Several ongoing clinical trials are now investigating these drugs in peritoneal mesothelioma more directly, including whether certain patients are more likely to benefit based on tumor type or genetic profile.

When It's Used

Immunotherapy may be considered:

• After chemotherapy has failed to control disease progression

• When CRS-HIPEC is not possible due to tumor spread or health concerns

• As part of a clinical trial exploring novel combinations or biomarkers

While not curative on its own, immunotherapy may stabilize disease, reduce tumor burden, or improve quality of life—especially when other options are limited.

Looking Ahead

As research continues, immunotherapy may play a growing role in both frontline and adjuvant treatment for peritoneal mesothelioma. Patients interested in immunotherapy should ask their oncologist whether any clinical trials are available at nearby academic or mesothelioma specialty centers.

Multimodal Therapy: When More Than One Approach Is Needed

Some patients benefit from neoadjuvant chemotherapy (before surgery) to shrink tumors or assess response, followed by CRS-HIPEC. Others receive adjuvant therapy afterward, especially if surgery could not fully remove the tumor or if poor prognostic features were present (e.g., biphasic histology, high Ki-67 index).

In the Brandl et al. (2020) study, patients with lower tumor burden (PCI ≤17) and low proliferation markers had better outcomes, emphasizing the need for a personalized, risk-adapted approach.

Palliative Care and Symptom Management

For patients who are not candidates for curative treatment, symptom relief remains a priority. Options include:

• Paracentesis for fluid removal in patients with recurrent ascites.

• Pain management using medications or nerve blocks.

• Nutritional support to address appetite loss and weight decline.

• Palliative chemotherapy or radiation to reduce tumor-related symptoms.

Even in advanced disease, integrating palliative interventions can improve quality of life and ease the burden of symptoms. Patients who are not candidates for surgery—or those who have already undergone standard treatment—may benefit from participation in clinical trials testing immunotherapy, targeted drugs, or gene-based approaches.

Legal and Financial Support for Accessing Treatment

CRS-HIPEC and other advanced treatments for peritoneal mesothelioma are often available only at specialized cancer centers. For many patients—especially those in rural or underserved areas—getting to those centers can involve major challenges. Travel costs, insurance limitations, and lack of local expertise can delay or even prevent access to life-extending care.

If you're facing these obstacles, know that help is available. Many cancer centers offer telemedicine consultations, travel assistance programs, or hospital-based financial counseling to help patients access expert care. National cancer organizations may also provide grants or logistical support.

Legal compensation can be a critical part of bridging the gap. Because asbestos exposure is the primary cause of mesothelioma, many patients qualify to pursue financial recovery through asbestos trust funds, lawsuits, or veterans’ benefits. These funds can help cover:

• Medical expenses, including surgery, imaging, and chemotherapy

• Travel and lodging near treatment centers

• Lost income or early retirement

• Out-of-pocket costs not covered by insurance

Compensation also holds negligent companies accountable for the harm caused by their products. If you or a loved one has been diagnosed with peritoneal mesothelioma and has a known or suspected history of asbestos exposure—even secondhand—we can help you explore your legal options.

Histological Subtypes of Peritoneal Mesothelioma and Their Relevance to Treatment and Prognosis

Peritoneal mesothelioma is histologically classified into three primary subtypes: epithelioid, sarcomatoid, and biphasic. However, recent studies show that these categories may oversimplify the true histologic diversity and prognostic variation seen in peritoneal disease. More detailed subtyping—especially within the epithelioid group—offers clearer insight into survival outcomes and treatment response.

In a 73-patient study at the University of Maryland, Liu et al. (2014) found that histologic pattern, depth of invasion, and sarcomatoid features were strong predictors of survival. Epithelioid tumors were further divided into tubulopapillary and solid/deciduoid forms, each with distinct prognoses. Meanwhile, sarcomatoid and biphasic tumors carried the worst outcomes, consistent with previous data.

Epithelioid Peritoneal Mesothelioma

Epithelioid mesothelioma is the most common subtype and generally the most responsive to treatment. However, this group is heterogeneous and should be further subclassified:

• Tubulopapillary (TPM): Represents the best prognosis among invasive tumors. In the Liu et al. cohort, many TPM cases were non-invasive and had no deaths during follow-up. For invasive TPM, median survival was not reached.

• Solid/Deciduoid (S/DM): A more aggressive variant with deeper invasion and higher mitotic activity. Median survival was 47.2 months in one surgical series, intermediate between TPM and biphasic mesothelioma.

Treatment Considerations:

• CRS-HIPEC remains the standard of care, with outcomes highly dependent on tumor resectability and histologic pattern.

• Immunotherapy is under investigation for epithelioid tumors and may show greater promise in this group.

Learn more about epithelioid mesothelioma.

Sarcomatoid Peritoneal Mesothelioma

Pure sarcomatoid mesothelioma is exceedingly rare in the peritoneum, but when present, it carries the worst prognosis. In many cases, sarcomatoid features appear in biphasic tumors. These tumors tend to invade deeply, respond poorly to chemotherapy, and progress rapidly.

Treatment Considerations:

• Most patients are not surgical candidates.

• Systemic chemotherapy often has limited impact.

• Immunotherapy may offer limited benefit; case reports are under evaluation.

Learn more about sarcomatoid mesothelioma.

Biphasic Peritoneal Mesothelioma

Biphasic mesothelioma contains both epithelioid and sarcomatoid elements. In Liu et al.’s study, biphasic tumors had the shortest median overall survival—only 10.6 months—even when treated with CRS-HIPEC. All showed deep invasion into fat or adjacent organs.

Treatment Considerations:

• Surgery may be attempted in select cases, but outcomes are generally poor.

• Chemotherapy and palliative care are often prioritized due to the aggressive behavior of these tumors.

• The presence of sarcomatoid elements drives treatment resistance and worsens prognosis.

Learn more about biphasic mesothelioma.

Low-Grade Variants: WDPM and MCM

Well-Differentiated Papillary Mesothelioma (WDPM) and Multicystic Mesothelioma (MCM) are rare, low-grade forms that occur more often in younger women. Though generally indolent, they can recur and—rarely—undergo malignant transformation.

• WDPM: Excellent prognosis with no deaths reported in Liu et al. or Sharma et al. studies. Disease may recur but behaves slowly.

• MCM: Also associated with long-term survival but may recur in up to 50% of cases. A small number of reports suggest possible progression to invasive disease in rare instances.

These tumors often require surveillance rather than radical surgery, though CRS may be performed if the disease is symptomatic or progressing.

Histological Subtypes of Peritoneal Mesothelioma and Their Effect on Treatment

Why Histology and Invasion Matter

Understanding the histological subtype of peritoneal mesothelioma is essential—but not sufficient on its own. While subtype strongly influences prognosis and treatment planning, recent studies show that other pathological features, especially depth of invasion and sarcomatoid differentiation, are equally or more important in predicting patient outcomes.

In Liu et al.’s multivariate analysis of 73 patients, the most significant adverse prognostic factors were:

• Sarcomatoid histology

• Invasion into fat or adjacent structures (such as bowel, liver, or diaphragm)

• Presence of inflammatory stromal response

• Incomplete cytoreduction (CCR 2–3)

These findings reinforce a critical point: effective treatment decisions depend on more than just tumor type. They must also consider how deeply the tumor has invaded, whether a complete surgical resection is feasible, and what biological behaviors are present under the microscope.

Histology still plays a vital role in:

• Prognosis – Median survival varies dramatically by subtype, with epithelioid tumors generally associated with better outcomes and biphasic or sarcomatoid tumors indicating more aggressive disease.

• Treatment Planning – Whether a patient qualifies for CRS-HIPEC often depends on both subtype and invasion pattern.

• Clinical Trials – Many emerging therapies, particularly immunotherapies, are being developed and tested based on histologic response.

Accurate and detailed histological evaluation—including subtype, invasion depth, and presence of sarcomatoid features—is essential to guiding treatment, predicting prognosis, and identifying patients who may benefit from novel therapies.

Prognosis and Survival Rates for Peritoneal Mesothelioma

Peritoneal mesothelioma is a rare but often treatable form of mesothelioma, especially when diagnosed early and managed at a specialized center. Prognosis depends on several key factors, including tumor burden, histological subtype, surgical resectability, patient age, and overall health. Advances in surgical techniques—particularly cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC)—have significantly improved survival in appropriately selected patients.

What Affects Prognosis?

Tumor Burden and Surgical Resectability

The Peritoneal Cancer Index (PCI) and Completeness of Cytoreduction (CCR) are among the most powerful predictors of outcome:

• Low PCI (≤10) and complete cytoreduction (CCR-0 or CCR-1) are associated with the longest survival. In some studies, patients with these features had median survival well over 60 months (Liu et al., 2014; Yaşar et al., 2024).

• High PCI scores, incomplete cytoreduction (CCR 2–3), or involvement of the bowel serosa typically indicate more advanced disease and shorter survival.

Histological Subtype

As with other forms of mesothelioma, histology plays a major role in prognosis:

• Epithelioid (especially tubulopapillary): Most favorable outcomes; many patients survive several years after CRS-HIPEC.

• Solid/deciduoid epithelioid: Intermediate prognosis, with median survival around 47 months.

• Biphasic: Poor outcomes; median survival just 10.6 months in one surgical cohort (Liu et al., 2014).

• Sarcomatoid: Very rare and associated with aggressive behavior and poor response to treatment.

These findings are consistent across multiple institutional and multicenter studies, reinforcing the importance of accurate histologic diagnosis.

Depth of Invasion and Tumor Biology

In addition to histology, certain microscopic features are strongly linked to survival:

• Invasion into fat or adjacent organs (grade 2–3)

• Sarcomatoid differentiation

• Presence of inflammatory stromal response

• Tumor necrosis

• High mitotic activity or nuclear grade

In multivariate analysis, invasion depth and sarcomatoid features remained among the most statistically significant predictors of poor survival (Liu et al., 2014).

Age and Overall Health

Age also plays a role in prognosis. In one cohort, patients under 55 had a median survival of nearly 10 years, while those over 55 had a median survival closer to 4 years (Liu et al., 2014). Younger, healthier patients are more likely to tolerate aggressive treatments and qualify for surgery.

Survival Rates of Peritoneal Mesothelioma

While outcomes vary widely depending on tumor characteristics and treatment, recent studies show meaningful improvements in survival for many patients:

• In a 2024 multi-center study, patients treated with CRS-HIPEC had a median survival of 44.6 months, with a 1-year survival rate of 95% and 2-year survival of 83% (Yaşar et al., 2024).

• In the UK-Ireland national cohort, the 3-year overall survival for all patients was 62.6%, including those who did not undergo surgery (Brandl et al., 2020).

• Patients with biphasic or sarcomatoid tumors, high PCI, or incomplete cytoreduction had median survival under 12 months across multiple datasets (Liu et al., 2014; Sharma et al., 2011).

These numbers compare favorably to earlier eras, where median survival was often less than 12 months using systemic chemotherapy alone.

Importance of Early Diagnosis and Specialized Treatment

Peritoneal mesothelioma is best managed at experienced centers capable of performing CRS-HIPEC. Patients with low-volume disease and favorable histology have the highest chance of long-term survival. Even when cure isn’t possible, many patients can benefit from chemotherapy, palliative surgery, or participation in clinical trials.

Because this cancer often goes undiagnosed until advanced stages, patients with a history of asbestos exposure—or unexplained abdominal symptoms—should be evaluated by a multidisciplinary mesothelioma team as early as possible.

Living Beyond Expectations

A diagnosis of peritoneal mesothelioma is serious—but it is not without hope. For many patients, particularly those diagnosed early and treated with cytoreductive surgery and HIPEC, survival far beyond initial expectations is possible. In recent studies, patients with low tumor burden, favorable histology, and complete surgical resection have lived for five years or more after treatment—some even longer (Yaşar et al., 2024; Liu et al., 2014).

Improvements in surgical techniques, chemotherapy protocols, and supportive care continue to extend both survival and quality of life. More patients are not just living longer—but living better—with access to experienced medical teams, legal support to fund care, and emotional and practical resources that help them adapt to life after diagnosis. Research is ongoing, and new treatments are being tested every year. Even in advanced cases, there is always reason to explore your options and ask what’s next.

Living with Peritoneal Mesothelioma

Peritoneal mesothelioma is physically and emotionally demanding—not just for the patient, but for their entire support network. The disease often arises unexpectedly, presents with vague symptoms, and may not be recognized until advanced stages. However, with the right medical care and support, many people go on to lead meaningful, active lives during and after treatment.

This section offers guidance on how to navigate life with peritoneal mesothelioma—from managing symptoms and side effects to preserving emotional well-being and accessing supportive services.

Managing Symptoms of Peritoneal Mesothelioma

Common symptoms include abdominal pain, swelling, fatigue, appetite loss, and the impact of ascites (fluid buildup in the abdominal cavity). These symptoms may fluctuate during treatment and recovery, but they can often be managed effectively with medical and lifestyle interventions.

Managing Ascites (Abdominal Fluid Build-Up)

• Ascites is a hallmark symptom in many cases and can cause bloating, heaviness, or difficulty eating.

• Paracentesis (draining the fluid with a needle) offers temporary relief and may be repeated as needed.

• Surgical cytoreduction with HIPEC often reduces or eliminates ascites in eligible patients.

Pain and Digestive Discomfort

• Tumor growth or inflammation may cause cramping, bowel changes, or discomfort.

• Pain is usually managed with oral medications, anti-nausea agents, or—when needed—palliative procedures such as surgical debulking or nerve blocks.

Nutritional Support

• Appetite and digestion may be impaired during treatment or recovery.

• A registered dietitian can help create a high-protein, nutrient-rich eating plan.

• Small, frequent meals, hydration, and avoiding gas-producing foods can ease discomfort.

• Nutritional supplements and shakes may be beneficial, particularly during chemotherapy.

Emotional and Psychological Well-Being

Like all serious illnesses, peritoneal mesothelioma takes a toll on mental health. Fear, anxiety, grief, and fatigue are common—even in early-stage patients. But emotional support can make a significant difference in coping and resilience.

Support Strategies:

• Therapy and Counseling: A licensed therapist—especially one familiar with cancer care—can help process the emotional impact of diagnosis and treatment.

• Support Groups: Many patients benefit from connecting with others through rare cancer or mesothelioma-specific support groups, both in-person and online.

• Mindfulness and Stress Reduction: Meditation, journaling, guided breathing, and gentle movement practices like yoga or tai chi can help patients feel more centered and in control.

• Family Dialogue: Open conversations with partners, children, and caregivers can reduce isolation and strengthen bonds during a difficult time.

Monitoring and Long-Term Follow-Up

Even after treatment, peritoneal mesothelioma requires close follow-up due to the risk of recurrence—especially within the first 1–2 years.

Most follow-up plans include:

• Regular CT or MRI imaging to detect early signs of recurrence

• Blood work and symptom review

• Ongoing care coordination with surgical and oncology teams

Patients should:

• Track any new symptoms or changes in appetite, digestion, or energy

• Maintain communication with a mesothelioma-specialized care team

• Consider integrative approaches, including nutrition, palliative care, and mental health support

Financial and Legal Planning

Because peritoneal mesothelioma is strongly linked to occupational asbestos exposure, many patients are eligible for legal compensation. These funds can help cover treatment costs, travel for specialist care, lost wages, and home support needs.

If you or a loved one has been diagnosed with peritoneal mesothelioma and has a known (or suspected) history of asbestos exposure—even secondhand—legal options may be available. Pursuing a claim not only helps with financial burdens, but also holds responsible companies accountable.

Moving Forward with Support

Living with peritoneal mesothelioma brings profound challenges—but it also offers opportunities for resilience, connection, and meaningful care. Whether you're newly diagnosed, undergoing treatment, or navigating survivorship, know that you’re not alone. Advances in treatment, access to specialized centers, and growing support communities are helping patients live longer, stay active, and protect their quality of life—even in the face of this rare and aggressive disease.

Legal Options for Peritoneal Mesothelioma

Although peritoneal mesothelioma is rare, it is strongly and consistently linked to asbestos exposure. Multiple studies—including those involving surgical and pathology cohorts—confirm that many patients had known or likely occupational or secondary asbestos exposure, even when that exposure wasn’t immediately obvious. This exposure history, combined with decades of scientific and legal precedent, gives most peritoneal mesothelioma patients the right to pursue financial compensation.

That compensation can help cover the cost of treatment, provide for loved ones, and unlock access to the best care available. Below are the primary legal and financial options available to patients and their families.

Asbestos Trust Fund Claims

What They Are

When many asbestos companies filed for bankruptcy, courts required them to create trust funds to compensate individuals harmed by their products. These funds offer a way to seek compensation without having to go to trial.

Why They Matter for Peritoneal Mesothelioma Patients

• Trusts often prioritize mesothelioma cases—especially peritoneal mesothelioma—for faster review.

• Many patients receive compensation within 30 to 90 days of filing a properly documented claim.

• Living claimants typically receive higher payments than claims filed after death.

How We Help

Our legal team manages the entire trust claim process for you—from gathering exposure documentation to submitting and tracking your claim—so you can focus on your care and family.
[Learn more about asbestos trust fund claims →]

What They Involve

A mesothelioma lawsuit is a civil claim against companies that manufactured, supplied, or failed to warn about asbestos-containing products. These lawsuits can result in settlements or jury verdicts, sometimes amounting to significant compensation.

Types of Lawsuits

• Product Liability: Against manufacturers or distributors of asbestos products.

• Premises Liability: Against employers or property owners responsible for unsafe working conditions.

• Wrongful Death: Filed by family members after the loss of a loved one.

Why They Matter

These lawsuits don’t just recover money—they expose corporate misconduct and help prevent future harm. Compensation from these claims can help:

• Cover the cost of surgery, HIPEC, chemotherapy, and long-term monitoring

• Replace lost income and retirement savings

• Provide security for surviving spouses and dependents

How We Help

We handle every step of the process, including:

• Identifying responsible companies—even decades after your exposure occurred

• Gathering evidence from job sites, product databases, and medical records

• Filing in mesothelioma-priority courts to ensure expedited review

• Negotiating settlements or taking your case to trial

• Coordinating with your medical team so treatment is never disrupted

• Advancing all legal costs—our clients never pay out of pocket

We work on a contingency basis, meaning you pay nothing unless we recover compensation for you. [Learn more about mesothelioma lawsuits →]

Social Security Disability Benefits (SSDI) for Mesothelioma Patients

Eligibility

Peritoneal mesothelioma qualifies as a “Compassionate Allowance” condition under Social Security rules. If you are no longer able to work due to your illness, you may be eligible for SSDI benefits.

To qualify, you must:

• Have a confirmed diagnosis of malignant peritoneal mesothelioma

• Be unable to maintain gainful employment

• Have sufficient work history and credits under the Social Security system

Available Benefits

• Monthly SSDI Payments based on your work history

• Medicare Coverage typically begins after 24 months of SSDI approval—even if you're under 65

How We Help

We assist with:

• Preparing and submitting your SSDI application

• Ensuring your medical documentation meets Social Security criteria

• Navigating appeals if your initial claim is denied

[Learn more about SSDI benefits for mesothelioma patients →]

Veterans’ Benefits for Asbestos Exposure

Eligibility

Veterans who were exposed to asbestos during military service—particularly in naval shipyards, boiler rooms, or maintenance roles—may qualify for benefits through the U.S. Department of Veterans Affairs (VA).

Available Benefits

• Disability Compensation: Monthly tax-free payments based on the severity of your illness

• Dependency and Indemnity Compensation (DIC): Financial support for surviving spouses and dependents after a veteran’s death from service-connected mesothelioma

How We Help

We help veterans and their families:

• Document military asbestos exposure

• File initial VA claims or appeals

• Coordinate VA benefits with legal claims to maximize financial support

[Learn more about veterans’ asbestos exposure benefits →]

Acting Quickly Is Crucial

Every state has a statute of limitations—a legal deadline—for filing asbestos-related claims. In many cases, the clock starts ticking from the date of diagnosis. If you wait too long, you may lose the ability to file altogether. Even if you're not sure how or when the exposure occurred, talking to a qualified attorney can help protect your rights.

Compensation Can Make a Life-Changing Difference

Legal compensation doesn’t just hold companies accountable—it empowers patients and families to make the best decisions for their care. It can help:

• Pay for lifesaving treatments like CRS-HIPEC

• Travel to see top specialists or get second opinions

• Offset lost wages or early retirement

• Protect your family's future and reduce financial stress

Take the First Step Today

If you or someone you love has been diagnosed with peritoneal mesothelioma, don’t wait. We’ve helped thousands of families get justice and financial relief after an asbestos diagnosis. We know the legal system—and we understand the human impact of this disease.

Call us today at 833-4-ASBESTOS to explore your legal options and begin the path to recovery and peace of mind.

References:

1. Brandl A, Westbrook S, Nunn S, et al. Clinical and surgical outcomes of patients with peritoneal mesothelioma discussed at a monthly national multidisciplinary team video-conference meeting. BJS Open. 2020;4(3):449–456. doi:10.1002/bjs5.50256.

2. Malpica A, Euscher ED, Marques-Piubelli ML, et al. Malignant mesothelioma of the peritoneum in women: A clinicopathologic study of 164 cases. Am J Surg Pathol. 2020;44(6):782–798. doi:10.1097/PAS.0000000000001445.

3. Yaşar S, Yılmaz F, Utkan G, et al. Analysis of treatment strategies and outcomes in malignant peritoneal mesothelioma: insights from a multi-center study. Ann Surg Oncol. 2024;31:6228–6236. doi:10.1245/s10434-024-15506-3.

4. Liu S, Staats P, Lee M, Alexander HR, Burke AP. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients. Pathology. 2014;46(7):604–609. doi:10.1097/PAT.0000000000000181

5. Sharma H, Bell I, Schofield J, Bird G. Primary peritoneal mesothelioma: case series and literature review. Clin Res Hepatol Gastroenterol. 2011;35(1):55–59. doi:10.1016/j.gcb.2010.07.016

If you’ve been diagnosed with peritoneal mesothelioma—or are helping a loved one through it—don’t go it alone. We can help you understand your options, connect with specialists, and pursue the compensation you deserve. Contact us today for a free consultation.